From several recent publications we know that the mortality can be as high as 17% and ranges probably around 10%, that about 35% may suffer from significant intellectual and/or neurological handicaps, that hearing defects occur in 2-3% of the cases and that the so-called normal survivors are significantly different from matched controls as to their intellectual performance (SPROLES et al. 1969 ; SELL et al. 1972; GAMSTORP and KLOCKHOFF 1974 ).
Furthermore, with rigid therapeutic regimes some side effects became apparent which, although rare or even remote, require some second thoughts about risks versus residuals (SCHROTER 1974, GAMSTORP and KLOCKHOFF 1974) .
The controversy about adequate treatment of H. influenzae meningitis again concentrates around the question "chloramphenicol versus ampicillin". Neither in vitro (KHAN et al. 1966 ) nor clinical studies , FLEMING et al. 1965 ) could find one drug principally superior to the other. This finding is particularly important since sometimes the bacteriocidic effect of ampicillin was discussed against the bacteriostatic effect of chloramphenicol. Theoretically, chloramphenicol has some advantage because of a consistent serum/CSF ratio of about 40% during the whole course of the treatment rather independent from CSF cell count or protein (MCCRUMR et al. 1951 ). CSF ampicillin levels, on the other hand, were found to be more inconsistent and the factors which influence the serum/CSF ratio of this drug are still only partly known: dose, route and interval of administration, CSF protein and meningeal inflammatory reaction, renal function even without clinical signs of failure or diuresis, shock etc. Even if patients with overt renal failure were excluded the CSF values were unpredictable, although with 150-200 mg/kg/day during the first three days of treatment -when cell count and protein were high -"most of the time" sufficient levels were reached ). I t is noteworthy, however, that in 12 o u t of 128 CSF specimens these authors could not detect ampicillin (less than 0,03 mg! ml): t w o of these patients were treated with ampicillin for meningococcal, four for pneumococcal and six for H. influenzae meningitis. In all cases lack of ampicillin in the CSF was also noted during the first three days of treatment, when it is particularly dangerous. Because of the reported variance in CSF ampicillin levels we ourselves did never change to ampicillin in the treatment of the meningitides and continued t o use double therapy (penicillin and chloramphenicol) in purulent meningitis of unknown origin and chloramphcnicol alone in a dose of 100 mglliglday, once H . influenzae was clearly diagnosed in the cultures. From 1963-1973 twenty-three consecutive cases were thus treated. In the earlier years treatment was continued sometimes as long as 20-25 days. Later, according t o international agreement, the drug was discontinued 4 days after the child became afebrile, provided that the CSF cell-count was mononuclear and below 30 per cubic millimeter, that the protein concentration was less than 50 mg1100 ml and that all other signs of an acute inflammatory reaction were disappearing. Thus, the duration of treatment was reduced to less than 15 days. However, we still always exceed the socalled maximum dose of 700 mglkg chloramphenicol in children with H. influenzae meningitis. All o u r patients were followed both by a pediatric neurologist and a psychologist. From the 23 children only one died (30 minutes after admission), one child, who was admitted 7 days after the onset of the illness has neuro-psychiatric sequelze and only one other has a hearing defect. Thus, 84% of our patients recovered completely. Severe hematologic o r other side effects of chloramphenicol were not seen in this hospital.
However, at the moment for some authors it may still not seem justified to treat every purulent meningitis of unknown origin o r every H. influenzae meningitis with chloramphenicol. The situation becomes again debatable, if Dr. GAMSTORP'S (1974) experience with a high percentage of hearing defects after ampicillin therapy of H. influenzae meningitis can be demonstrated in a larger series of cases and if ampicillin resistent H. influenzae will be found in one's own area. Once can at least make a strong case for chloramphenicol in all those patients with proven o r suspected H. influenzae meningitis, in which neuropsychiatric symptoms such as apathy o r even unconsciousness, convulsions and shock as well as poor meningeal inflammatory reaction do not allow t o run any risk of therapeutic delay due t o inconsistent CSF drug levels o r due t o questionable sensitivity of the organism. From the data reported so far no support can be derived for using ampicillin during the first days of treatment and then changing to chloramphenicol, when CSF cell count and protein are such, that the ampicillin concentration in the CSF is likely t o be very low. There ist strong evidence from the literature, that the efficiency of the treatment during the first days determines the ultimate outcome. Practically all deaths and the major complications occur during the first 3 days. A combination of ampicillin and chloramphenicol is probably dangerous since the two drugs are likely t o be antagonistic (HALTALIN and SMITH
1971).
In this issue of our Journal we asked Dr. LORRER t o present his view on the treatment of H. influenzae meningitis, which differs somewhat from current practice but, nevertheless, seems t o be equally succesful.
